Harvard Bioscience (HBIO) Accumulated Depreciation & Amortization (2010 - 2025)

Harvard Bioscience (HBIO) has 16 years of Accumulated Depreciation & Amortization data on file, last reported at $18.1 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 14.51% year-over-year to $18.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.1 million (up 14.51% YoY) and the FY2025 annual result came in at $18.1 million, up 14.51% from the prior year.
• Accumulated Depreciation & Amortization grew to $18.1 million in Q4 2025 per HBIO's latest filing, from $15.8 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $18.1 million in Q4 2025 and bottomed at $14.4 million in Q4 2023.
• The 5-year median for Accumulated Depreciation & Amortization is $14.8 million (2022), against an average of $15.5 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization dropped 12.94%; it then increased 14.51% in 2025.
• Tracing HBIO's Accumulated Depreciation & Amortization over 5 years: stood at $14.4 million in 2021, then rose by 2.75% to $14.8 million in 2022, then slipped by 3.11% to $14.4 million in 2023, then rose by 9.98% to $15.8 million in 2024, then rose by 14.51% to $18.1 million in 2025.
• Per Business Quant, the three latest HBIO Accumulated Depreciation & Amortization figures stand at $18.1 million (Q4 2025), $15.8 million (Q4 2024), and $14.4 million (Q4 2023).

Peer Comparison